INHIBITION BY SUMATRIPTAN OF CENTRAL TRIGEMINAL NEURONS ONLY AFTER BLOOD-BRAIN-BARRIER DISRUPTION
INHIBITION BY SUMATRIPTAN OF CENTRAL TRIGEMINAL NEURONS ONLY AFTER BLOOD-BRAIN-BARRIER DISRUPTION
复制标题
DOI：
10.1111/j.1476-5381.1993.tb13643.x
复制
发表时间：
1993-07-01
影响因子：
7.3
通讯作者：
GOADSBY, PJ
中科院分区：
文献类型：
--
作者：
KAUBE, H;HOSKIN, KL;GOADSBY, PJ
5-羟色胺（5-HT1）样激动剂舒马曲坦对缓解偏头痛及其伴随症状非常有效实验证据表明，它的作用部位可能在颅血管或颅三叉神经支配上，或两者兼有，因为在正常情况下，舒马曲坦不易通过血脑屏障。然而，目前尚不清楚偏头痛发作时血脑屏障是正常还是异常在本研究中，在电刺激上矢状窦时，监测三叉神经中枢神经元的单细胞活动和体感诱发电位静脉注射舒马曲坦（100马克千克-1）不会改变三叉神经诱发活动，除非通过高渗甘露醇溶液的输注增加了血脑屏障的通透性。在血脑屏障破坏后，舒马匹坦使诱发电位峰对峰幅度降低了40 +/- 6%，使单个单元的放电概率降低了30 +/- 9%。在对照动物中单独输注甘露醇没有引起诱发电位或单位活动的变化数据表明，在正常情况下，舒马匹坦没有足够的途径进入三叉神经来改变它们的功能。
1 The 5-hydroxytryptamine (5-HT1)-like agonist, sumatriptan, is highly efficient in the relief of migraine headache and its accompanying symptoms.2 Experimental evidence has indicated that its site of action may be on the cranial vessels or on the trigeminal innervation of the cranium, or both, since sumatriptan does not pass the blood-brain barrier easily under normal circumstances. It is, however, not clear whether the blood-brain barrier is normal or abnormal during a migraine attack.3 In this study, single unit activity and trigeminal somatosensory evoked potentials in central trigeminal neurones were monitored during electrical stimulation of the superior sagittal sinus.4 Intravenous administration of sumatriptan (100 mug kg-1) did not alter trigeminal evoked activity unless the permeability of the blood-brain barrier had been increased by infusion of an hyperosmolar mannitol solution. After blood-brain barrier disruption, sumatriptan decreased the peak-to-peak amplitude of evoked potentials by 40 +/- 6% and the probability of firing of single units by 30 +/- 9%. Mannitol infusions alone in control animals caused no changes in evoked potentials or single unit activity.5 The data suggest that in normal circumstances sumatriptan does not have sufficient access to trigeminal neurones to alter their function.